Small molecules still represent the lion's share of the pharmaceutical market, despite the rise in importance of biologics in recent years. But the nature of many of these compounds is changing, with many now posing challenges in the manufacturing plant and in formulation. This e-book will look at some of those challenges, and what can be done to address them.
- Stabilized amorphous APIs: a way to improve bioavailability
- Highly potent compounds: assessing the risks and handling them safely
- HPAPI complexity: adaptation of existing processes to enable handling of HPAPIs in a safe and efficient manner